Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1433 • ACR Convergence 2024
Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients
Andre Lucas Ribeiro¹, Sydney Thib², Kangping Cui³, Sahil Koppikar⁴ and Lihi Eder⁵, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²Women's College Research Institute, Toronto, Canada, ³Sunnybrook Hospital, Toronto, Gravenhurst, ON, Canada, ⁴Women's College Hospital & University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Ultrasound (US) is a valuable tool for enhancing disease activity assessment in psoriatic arthritis (PsA) by providing detailed visualization of both inflammatory and structural…
Abstract Number: 1470 • ACR Convergence 2024
Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement
Alen Zabotti¹, Alexis Ogdie², Masato Okada³, Rebecca Bolce⁴, Jeffrey Lisse⁵, Marcus Ngantcha⁵, mohamed taher⁵, Khai Jing Ng⁶ and Dennis McGonagle⁷, ¹Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Udine, Italy, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³St. Luke's International Hospital, Tokyo, Japan, ⁴Eli Lilly and Company, Cincinnati, OH, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Madrid, Spain, ⁷National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: Nails are a challenging body area to treat in patients (pts) with psoriatic arthritis (PsA)1. Previous research found that nail psoriasis is closely related…
Abstract Number: 1924 • ACR Convergence 2024
Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials
Dania Kaur¹, Fizza Zulfiqar², Akshee Batra³ and Abhinav Vyas⁴, ¹North Alabama Medical Center, Muscle Shoals, AL, ²Trinity Health Oakland/Wayne State University, Pontiac, MI, ³University of Miami, Miami, FL, ⁴Vanderbilt University Medical Center, Nahville, TN
Background/Purpose: To develop effective novel treatment strategies for psoriatic arthritis that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
Abstract Number: 2318 • ACR Convergence 2024
Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
Fadi Kharouf¹, Pankti Mehta², Shangyi Gao², Daniel Pereira³, Richard Cook⁴, Dafna Gladman⁵ and Vinod Chandran⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis typically precedes psoriatic arthritis (PsA), with a variable transition period. In this study, we aimed to explore whether the time interval between the…
Abstract Number: 2335 • ACR Convergence 2024
Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study
Birte Coppers¹, Sara Bayat², Koray Tascilar¹, Daniela Bohr¹, Larissa Valor¹, David Simon³, Filippo Fagni¹, Giulia Corte², Axel Hueber⁴, Harriet Morf¹, verena schönau¹, Michael Sticherling⁵, eva manger¹, sonja liehr¹, Juergen Rech¹, Georg Schett⁶, Arnd Kleyer⁷ and Anna-Maria Liphardt¹, and Birte Coppers and Sara Bayat, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Charité - Universittsmedizin Berlin, Berlin, Germany, ⁴Klinikum Nuernberg, Nuernberg, Germany, ⁵FAU Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁷Charité - Universittsmedizin Berlin, Erlangen, Germany
Background/Purpose: Patients with skin psoriasis (Pso) have an increased risk of developing psoriatic arthritis (PsA) (6-42%) compared to the general population (0.02-0.42%) [1]. Early diagnosis…
Abstract Number: 2356 • ACR Convergence 2024
Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
KURT OELKE¹, Emily Edson Heredia², Sarah Ross², Jeffrey Lisse², Jennifer Pustizzi², Ali Sheikhi Mehrabadi², Natalia Bello², Frederick Murphy³, Shikha Singla⁴ and Siba Raychaudhuri⁵, ¹Rheumatic Disease Center, Glendale, WI, ²Eli Lilly and Company, Indianapolis, IN, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴Medical College of Wisconsin, Milwaukee, WI, ⁵UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated efficacy in treating psoriatic arthritis (PsA) in Phase 3/4 clinical trials…
Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Stephen Pennington¹, Ruoyi Zhou², Jonathan Brady², Bruna Wundervald², Andrew Parnell³, Ciarán Duffy², Robert Perryman², James Waddington⁴, Neil McHugh⁵, Deepak Jadon⁶, David Simon⁷, Filippo Fagni⁸, Georg Schett⁹, Fraser Morton¹⁰, Aurelie Najm¹⁰, Stefan Siebert¹¹, Laura Coates¹² and Oliver FitzGerald¹³, ¹UCD, Dublin, Dublin, Ireland, ²Atturos, DUBLIN, Dublin, Ireland, ³NUIM, Maynooth, Ireland, ⁴Agilent, Manchester, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶Cambridge University, Cambridge, United Kingdom, ⁷Charité - Universittsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹³UCD, Dublin 6, Dublin, Ireland
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Alan Kivitz¹, Elena Tomaselli Muensterman², Arthur Kavanaugh³, Désirée van der Heijde⁴, Piotr A. Klimiuk⁵, Guillermo Valenzuela⁶, Eva Dokoupilova⁷, Gabrielle Poirier⁸, Bhaskar Srivastava⁸, Sue Dasen⁸, Xinyan Zhang⁸, Mona Trivedi², Haoling Holly Weng⁹, Ting Hong¹⁰, Peter Pothula¹⁰ and Xenofon Baraliakos¹¹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Division of Rheumatology, Allergy & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Białystok, Poland, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University and MEDICAL PLUS, s.r.o., Brno and Uherské Hradiště, Czech Republic, ⁸Nimbus Discovery, Inc., Boston, MA, ⁹HW MedAdvice LLC, San Diego, CA, ¹⁰Takeda Development Center Americas, Inc., Boston, MA, ¹¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 0491 • ACR Convergence 2023
Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound
rodrigo garcía salinas¹, Jonatan Mareco², Santiago Ruta², RONALD PEREZ², Felica Almada² and Sebastián Juan Magri³, ¹Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The psoriasis- to- psoriatic arthritis (PsA) transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive…
Abstract Number: 0507 • ACR Convergence 2023
The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis
Antoni Chan and NiSoe Nwe, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Patient-reported outcome measures (PROMs) are important tools for evaluating disease activity, functional status, and quality of life in patients with psoriatic arthritis (PsA). The…
Abstract Number: 0966 • ACR Convergence 2023
The Burden of Oligoarticular Psoriatic Arthritis in the United States
Abisola Olopoenia¹, Ashley Martin², Kate Orroth³, Cynthia Deignan⁴, Myriam Cordey⁵ and Dafna Gladman⁶, ¹Cerner Enviza, North Kansas City, MO, ²BluePath Solutions, Los Angeles, CA, ³Amgen, Inc., Manhattan Beach, CA, ⁴Amgen, Inc., Agoura Hills, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
Abstract Number: 1413 • ACR Convergence 2023
Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST
Philip J. Mease¹, Alexis R Ogdie², Kristina Callis Duffin³, Jyotsna Reddy⁴, Rebecca Wang⁴, Shauna Jardon⁴ and Laura Coates⁵, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³University of Utah, Salt Lake City, UT, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: The modified minimal disease activity (MDA-Joints) is a novel composite endpoint to assess disease activity and treatment effect in PsA based on a criteria…
Abstract Number: 1430 • ACR Convergence 2023
A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients
Esther Espartal López¹, Xabier Michelena Vegas², Sara Marsal Barril¹, Alex Rovira³, Deborah Pareto³ and Alba Erra Duran¹, ¹Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ²Hospital Universitari Vall Hebron, Barcelona, Spain, ³Vall Hebron University Hospital, Section of Neuroradiology (Department of Radiology, IDI), Barcelona, Spain
Background/Purpose: Inflammatory cytokines can alter the way the central nervous system processes pain as shown in patients with rheumatoid arthritis. However, the relationship between TNFα…
Abstract Number: 1644 • ACR Convergence 2023
The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
Alba Boix-Amorós¹, Rebecca Blank², Adam Cantor¹, Jesus Sanz³, Ana Gutiérrez-Casbas⁴, Jordi Gratacos Masmitja⁵, Iago Rodríguez -Lago⁶, Elisa Trujillo⁷, Ignacio Marin-Jimenez⁸, Zulema Plaza⁹, Marta Domínguez¹⁰, Jose Federico Diaz-Gonzalez¹¹, Juan D Canete¹², Jose Scher¹³ and Jose Clemente¹, ¹Icahn School of Medicine, New York, NY, ²New York University, New York, NY, ³Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁵University Hospital Parc Taulí, Sabadell, Spain, ⁶Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Public Health System, Madrid, Spain, ⁹Universidad Autónoma de Madrid, Madrid, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Universitario de Canarias, La Laguna, Spain, ¹²Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹³New York University School of Medicine, New York, NY
Background/Purpose: Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD), despite not having any previous diagnosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].